您当前的位置:
首页 >
文章列表页 >
Targeting BMI1 mitigates chemoresistance in ovarian cancer
Short communication | 更新时间:2022-11-09
    • Targeting BMI1 mitigates chemoresistance in ovarian cancer

    • Targeting BMI1 mitigates chemoresistance in ovarian cancer

    • Genes & Diseases   2022年9卷第6期
    • 作者机构:

      1. Department of Obstetrics and Gynecology, University of Oklahoma Health Science Center,OK,Oklahoma City,USA,73104

      2. Department of Aging and Metabolism Research Program, Oklahoma Medical Research Foundation,OK,Oklahoma City,USA,73104

      3. Department of Pathology, University of Oklahoma Health Science Center,OK,Oklahoma City,USA,73104

      4. Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, California Northstate University, Elk Grove,CA,USA,95757

      5. Department of Cell Biology, University of Oklahoma Health Science Center,OK,Oklahoma City,USA,73104

      6. Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Science Center,OK,Oklahoma City,USA,73104

      7. PTC Therapeutics, Inc, South Plainfield,NJ,USA,07080

    • DOI:10.1016/j.gendis.2022.02.006    

      中图分类号:
    • 纸质出版日期:2022,

      网络出版日期:2022-11-1,

    扫 描 看 全 文

  • Targeting BMI1 mitigates chemoresistance in ovarian cancer[J]. Genes & Diseases, 2022,9(6). DOI: 10.1016/j.gendis.2022.02.006.

    Anindya Dey, Shailendra Kumar Dhar Dwivedi, Lin Wang, et al. Targeting BMI1 mitigates chemoresistance in ovarian cancer[J]. Genes & Diseases, 2022,9(6). DOI: 10.1016/j.gendis.2022.02.006.

  •  
  •  
查看原文

0

浏览量

0

下载量

0

CSCD

文章被引用时,请邮件提醒。
提交
工具集
下载
参考文献导出
分享
收藏
添加至我的专辑

相关文章

暂无数据

相关作者

暂无数据

相关机构

暂无数据
0